| Literature DB >> 30513644 |
Hong Liu1,2, Yifang Wan3,4, Yuxin Wang5,6, Yue Zhao7,8, Yue Zhang9,10, Ao Zhang11,12, Qiang Weng13, Meiyu Xu14,15.
Abstract
Fenitrothion (FNT), an organophosphate pesticide, exerts an immunotoxic effect on splenocytes. Dietary polyphenol compounds exert antioxidant, anticancer and antihypertensive effects. In this study, we investigated the effect of walnut polyphenol extract (WPE) on FNT-induced immunotoxicity in splenic lymphocytes in vitro. Treatment with WPE significantly increased the proliferation of FNT-exposed splenocytes, as evidenced by increases in the proportions of splenic T lymphocytes (CD3⁺ T cells) and T-cell subsets (CD8⁺ T cells), as well as the secretion of the T-cell-related cytokines interleukin (IL)-2, interferon-γ, IL-4 and granzyme B. These effects were associated with a reduction in oxidative stress, as evidenced by changes in the levels of hydroxyl radical, superoxide dismutase, glutathione peroxidase and malondialdehyde. Moreover, WPE decreased the FNT-induced overexpression of NADPH oxidase 2 and dual oxidase 1 by regulating Toll-like receptor 4 signaling in splenic T-cells. Taken together, these findings suggest that WPE protects against FNT-mediated immunotoxicity and improves immune function by inhibiting oxidative stress.Entities:
Keywords: Fenitrothion; immunotoxicity; oxidative stress; splenic T-lymphocytes; walnut polyphenol extract
Mesh:
Substances:
Year: 2018 PMID: 30513644 PMCID: PMC6315471 DOI: 10.3390/nu10121838
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Identification of phenolic compounds in walnut polyphenol extract (WPE) using HPLC-ESI-IT-TOF-MS 1 in the negative ion mode.
| No. | tR (min) | Measured [M-H]− | Predicted [M-H]− | MS/MS 2 Fragments ( | Identification | Molecular | Reference |
|---|---|---|---|---|---|---|---|
| 1 | 5.02 | 783.0773 | 783.0681 | 481.06, 300.99, 275.02 | Pedunculagin/casuariin isomer (bis-HHDP-glucose) | C34H24O22 | [ |
| 2 | 7.14 | 951.0762 | 951.0740 | 907.08, 783.07, 481.06, 300.99, 275.02 | PraecoxinA/ | C41H28O27 | [ |
| 3 | 8.31,10.14, 11.12, 11.89, 12.75 | 785.0845 | 785.0840 | 633.07, 483.08, 300.99, 275.02 | Tellimagrandin I isomer (digalloyl-HHDP-glucose) | C34H26O22 | [ |
| 4 | 8.96 | 633.0763 | 633.0720 | 463.05, 300.99 275.02 | Strictinin/isostrictinin isomers (galloyl-HHDP-glucose) | C27H22O18 | [ |
| 5 | 9.45, 12.29, 14.16 | 935.0813 | 935.0786 | 783.07, 633.07, 300.99, 275.02 | Tellimagrandin I isomer (digalloyl-HHDP-glucose) | C34H26O22 | [ |
| 6 | 9.79 | 301.0417 | 301.0347 | 151.04 | Quercetin | C15H10O7 | [ |
| 7 | 10.52, 11.60, 12.96, 16.24 | 933.0655 | 933.0630 | 631.06, 481.06, 450.99, 300.99 | Glansrin C isomer | C41H26O26 | [ |
| 8 | 10.67 | 907.0862 | 907.0837 | 783.07, 764.05, 481.06, 300.99, 275.02 | Heterophylliin E isomer | C40H28O25 | [ |
| 9 | 10.86 | 469.0040 | 469.0049 | 425.01, 300.99, 166.99 | Valoneic acid dilactone/Flavogallonic acid dilactone isomer | C21H10O13 | [ |
| 10 | 11.27 | 463.0512 | 463.0517 | 300.99 | Ellagic acid hexoside isomer | C20H16O13 | [ |
| 11 | 11.47, 12.13 | 635.0882 | 635.0877 | 483.08, 465.07, 423.06, 313.06, 169.01 | Trigalloyl-glucose isomer | C27H24O18 | [ |
| 12 | 12.55 | 1103.0873 | 1103.0850 | 1059.09, 935.07, 757.09, 633.07, 300.99 | Rugosin C/platycaryanin A/glansrin A isomer | C48H32O31 | [ |
| 13 | 13.14, 14.02, 14.32 | 787.0996 | 787.0996 | 635.08, 465.07, 169.01 | Tetragalloyl-glucose | C34H28O22 | [ |
| 14 | 13.39, 15.11 | 937.0956 | 937.0947 | 785.08, 635.08, 483.07, 300.99 | Tellimagrandin II/pterocaryanin C isomer | C41H30O26 | [ |
| 15 | 13.42 | 433.0399 | 433.0405 | 300.99 | Ellagic acid pentoside isomer | C19H14O12 | [ |
| 16 | 14.49 | 300.9989 | 300.9989 | 283.99, 257.01, 229.01, 185.02 | Ellagic acid | C14H6O8 | [ |
| 17 | 15.49, 18.90 | 1085.0771 | 1085.0740 | 783.07, 633.07, 450.99, 300.99 | Eucalbanin A/cornusiin B isomer | C48H30O30 | [ |
| 18 | 15.72 | 939.1120 | 939.1100 | 787.09, 769.09, 617.08 | 1,2,3,4,6-Pentagalloyl-glucose | C41H32O26 | [ |
| 19 | 17.03 | 433.1127 | 433.0772 | 300.03, 301.33 | Quercetin pentoside isomer | C20H18O11 | [ |
1 HPLC-ESI-IT-TOF-MS: High performance liquid chromatograph-electrospray ion source-ion trap-time of flight mass spectrometer- mass spectrometry. 2 MS/MS: Tandem mass spectrometry.
Identification of fraction 9 using HPLC-ESI-IT-TOF-MS in the negative ion mode.
| No. | tR (min) | Measured [M-H]− | Predicted [M-H]− | MS/MS Fragments ( | Identification | Molecular Formula | Reference |
|---|---|---|---|---|---|---|---|
| 1 | 9.79 | 301.0417 | 301.0347 | 150.00 | Quercetin | C15H10O7 | [ |
| 2 | 11.27 | 463.0512 | 463.0517 | 300.99 | Ellagic acid hexoside isomer | C20H16O13 | [ |
| 3 | 13.42 | 433.0396 | 433.0405 | 300.99 | Ellagic acid pentoside isomer | C19H14O12 | [ |
| 4 | 14.49 | 300.9990 | 300.9990 | 283.99, 257.01, 229.01 | Ellagic acid | C14H6O8 | [ |
Figure 1Effect of WPE on cytotoxicity in splenocytes exposed to FNT by MTT assay. Splenocytes were treated with fenitrothion (FNT, 10−4 M) or different concentrations (0.5, 1.0, 5.0 and 10.0 μg/mL) of WPE together with FNT. Results are presented as mean ± SD of three separate experiments. * p < 0.05 or ** p < 0.01, vs. untreated control; # p < 0.05 or ## p < 0.01 vs. FNT treatment.
Figure 2Effect of WPE on cytotoxicity of fenitrothion (FNT) in splenic lymphocyte subpopulations. Splenocytes were treated with FNT or WPE together with FNT for 48 h in the presence of Con A (5 μg/mL) or LPS (10 μg/mL). (A) Splenic cells stimulated with Con A (T lymphocytes) or (B) Splenic cells stimulated with LPS (B lymphocytes) viability was evaluated by an MTT assay. Controls were splenic cells cultured in medium contained Con A or LPS, untreated with FNT or WPE. Results shown are as mean ± SD of three separate experiments. ** p < 0.01, vs. control; ## p < 0.01 vs. FNT treatment.
Figure 3Percentages of various lymphocyte cell types as determined using flow cytometric analysis. (A) Cluster of differentiation (CD)3+ T-cells, (B) CD4+ T-cells, (C) CD8+ T-cells and (D) CD19+ B-cells in cells exposed to medium only (control), FNT or WPE together with FNT. Results shown are means ± SD of three separate experiments. * p < 0.05 vs. untreated control; # p < 0.05 vs. FNT treatment. (SSC: side scatter. FITC: fluorescein isothiocyanate.)
Figure 4Effects of WPE on select cytokine/granzyme production in splenocytes exposed to FNT. Levels of (A) interleukin (IL)-2, (B) interferon (IFN)-γ, (C) IL-4, (D) granzyme B and (E)IL-6 released into culture media were then measured by ELISA. Results shown are means ± SD of three separate experiments. * p < 0.05 or ** p < 0.01 vs. untreated control; # p < 0.05 vs. FNT treatment.
Figure 5Effects of WPE on the oxidative stress parameters in splenic cells exposed to FNT. Changes in (A) hydroxyl radical (•OH) content, (B) malondialdehyde (MDA) content, (C) superoxide dismutase (SOD) activity and (D) glutathione peroxidase (GSH-Px) activity in the cells were measured using specific assay kits. Controls were splenic cells cultured in medium, untreated with FNT or WPE. Results shown are means ± SD of three separate experiments. * p < 0.05 or ** p < 0.01 vs. untreated control; # p < 0.05 vs. FNT treatment.
Figure 6Effects of WPE on changes of the oxidative stress parameters induced by FNT in splenic cells stimulated by with Con A (5 μg/mL). Changes in (A) •OH content, (B) malondialdehyde (MDA) content, (C) SOD activity and (D) GSH-Px activity in the cells were measured using specific assay kits. Controls were splenic cells cultured in medium contained Con A or LPS, untreated with FNT or WPE. Results shown are means ± SD of three separate experiments. * p < 0.05 or ** p < 0.01 vs. control; # p < 0.05 or ## p < 0.01 vs. FNT treatment.
Figure 7Effects of WPE on the expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and TLR-4 in Splenic T Cells exposed to FNT in the presence of Con A (5 μg/mL). The expression of (A) NOX-2, (B) DUOX-1 and (C) TLR-4 in splenic T cells were measured using western blotting. Results shown are means ± SD of three separate experiments. ** p < 0.01 vs. untreated control; # p < 0.05 or ## p < 0.01 vs. FNT treatment.
Figure 8Effects of the 11 fractions on FNT induced immunotoxicity in splenocytes using MTT assay. Results shown are means ± SD of three separate experiments. * p < 0.05 or ** p < 0.01 vs. untreated control; # p < 0.05 or ## p < 0.01 vs. FNT treatment.